Bristol Myers Looks to buys MyoKardia for $13 bln

    Bristol Myers Looks to buys MyoKardia for $13 bln

    U.S. pharmacist Bristol Myers Squibb Co BMY.N said on Monday will purchase MyoKardia Inc MYOK.O for approximately $13 billion to expand his cardiac medicines company and minimise reliance on treatment of cancer.

    Bristol Myers to pay $225 a share in cash, a premium of 61.2 per cent to the closing price of MyoKardia on Friday.

    This deal follows the purchase of Celgene Corp last year of $74 billion by Bristol Myers, which merged the two largest drug firms in the world with the largest ever pharmaceutical deal.

    Bristol Myers Looks to buys MyoKardia for $13 bln

    Bristol Myers, who is a candidate for a chronic heart disorder that affects up to 200 000 people in the United States and Europe, would have access to the Mavacamten contract for Myokardia.

    Bristol Myers Squibb said it expects to explore mavacamten for additional indications and develop MyoKardia’s pipeline of other drugs.

    Bristol Myers Looks to buys MyoKardia for $13 bln

    Rajat Singh
    A Bioinformatics Masters degree from the G.N Khalsa Science and Commerce College (Mumbai). Blogger by choice and an enthusiastic person with a technical background and passion.

    Get in Touch

    Comments are closed.

    Related Articles

    Get in Touch


    Latest Posts